Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Nasopharyngeal Carcinoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 32 Breast Neoplasms 23 Triple Negative Breast Neoplasms 16 Prostatic Neoplasms 15 Fallopian Tube Neoplasms 11 Neoplasms 8 Pancreatic Neoplasms 6 Glioma 6 Endometrial Neoplasms 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Fanconi Anemia, Complementation Group D1 5 Cholangiocarcinoma 5 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Neoplasm Metastasis 3 Medulloblastoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Wilms Tumor 2 Uveal Melanoma 2

Interventions

Cisplatin 47 Gemcitabine 24 toripalimab 17 Radiotherapy, Intensity-Modulated 17 Capecitabine 16 Fluorouracil 15 Docetaxel 14 camrelizumab 13 nimotuzumab 12 apatinib 9 Drug Therapy 9 Radiotherapy 8 sintilimab 7 Nivolumab 7 tislelizumab 6 spartalizumab 6 endostar protein 6 Specimen Handling 6 Magnetic Resonance Spectroscopy 6 Bevacizumab 6 pembrolizumab 5 nedaplatin 5 Radiation 5 Immune Checkpoint Inhibitors 5 Endostatins 5 Chemoradiotherapy 5 Cetuximab 5 S 1 (combination) 4 Paclitaxel 4 Carboplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04825990 2022-04-07

POINT

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡